Novartis to buy Regulus Therapeutics for as much as $1.7 billion
Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

May 3, 2025 0
May 3, 2025 0
May 3, 2025 0
May 3, 2025 0
May 3, 2025 0
May 3, 2025 0
May 3, 2025 0
May 3, 2025 0
Or register with email
Apr 30, 2025 0
Apr 30, 2025 0
Apr 30, 2025 0
May 3, 2025 0
May 3, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.